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mood, positive well-being, self-control, general health, and vital-
ity. Pearson product moment correlation coefﬁcients were calcu-
lated between PGWB scales and A1c (baseline and end of study)
and between changes in PGWB scales and changes in A1c.
RESULTS: At baseline, lower A1c was associated with less
anxiety, less depressed mood, positive well-being, and better
overall psychological general well-being [range: r = -0.20 (posi-
tive well-being) to -0.23 (depressed mood), p < 0.05]. At end of
study, lower A1c was signiﬁcantly associated with overall well-
being and all domains [range: r = -0.19 (general health) to -0.42
(vitality), p < 0.05]. Changes in A1c were associated with
changes in vitality (r = 0.24, n = 111, p < 0.05) but not other
aspects of psychological general well-being. CONCLUSION:
Well-being is associated with patients’ clinical condition at base-
line and end of study as reﬂected in A1c, but, with the exception
of vitality, it is not associated with shorter-term changes in A1c.
Longer term follow-up may be needed to capture the impacts of
drug therapy on symptoms and complications, which are more
directly associated with well-being. Therefore, data collected
regarding patients’ psychological general well-being may serve as
a valuable supplement to clinical endpoints in diabetes drug
therapy evaluations of longer duration than 12 weeks.
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OBJECTIVE: Increase in insulin therapy prescribed to diabetes
patients has led to a demand for simple delivery devices that can
be used for effective, self-injection. Selecting the most appropri-
ate insulin delivery device for a given patient is likely to improve
patient compliance and promote accurate dosing. Perceived
usability and patient preference of the two preﬁlled insulin
analog pen devices (FlexPen and Humalog Pen) were compared.
METHODS: In a randomized, crossover study, 58 subjects (29
male, 29 female, average age 58 ± 16 years) who had not previ-
ously used insulin pen devices were randomized to test either
FlexPen or Humalog Pen for 2 days. The subjects were then
switched to alternate device for 2 days. Device assessments were
carried out at the end of each 2-day test period. Following
instructions, participants made simulated injections into a
sponge on the abdomen to determine the usability of each insulin
device. All subjects were tested for manual function and vision
prior to commencing the study. RESULTS: FlexPen was rated
signiﬁcantly better than Humalog Pen for each of the usability
questions: number legibility (p < 0.001), ease of dose setting 
(p < 0.001), ease of pressing the release button (p < 0.001), sta-
bility during injection (p < 0.001), simplicity (p < 0.001), con-
ﬁrmation of injection (p < 0.001), and appearance (p < 0.01).
No signiﬁcant differences were observed between the two devices
in measures of grip and portability. Overall, 83% subjects pre-
ferred FlexPen; 17% had no preference and no subjects preferred
Humalog Pen. FlexPen was also rated as superior to Humalog
Pen when subgroups of age, manual function and vision were
examined (p < 0.01 for each subgroup comparison of overall
score for each pen). CONCLUSIONS: The perceived usability
advantages of FlexPen were probably due to its scaled analogue
dial (which shows completion of injection) and larger dial
numbers. These results demonstrate that FlexPen achieved
patient preference with a wide range of patients, including those
with impaired vision and manual dexterity.
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OBJECTIVE: Peripheral neuropathy is a frequent complication
of diabetes often resulting in substantial persistent pain. Our goal
was to evaluate the impact of this pain on diabetes patients’ per-
ceived health status. METHODS: Endocrinologists, neurolo-
gists, anesthesiologists, and primary care physicians recruited
patients with a history of painful DPN (N = 255) between April
and October 2003. Patients completed a burden of illness survey
including questions on average and worst pain due to DPN
(modiﬁed Brief Pain Inventory-DPN [m-BPI-DPN] 0–10 scales,
where “0 = no pain” and “10 = pain as bad as you can imagine”),
health status (EuroQoL [EQ-5D]), and global overall health
(0–100 scale, where “0 = worst possible health” and “100 =
perfect health”). RESULTS: Patients were 61 ± 12.8 years old
(51.4% female), had diabetes for 12 ± 10.3 years and painful
DPN for 6.4 ± 6.4 years. Average and worst pain scores were
5.0 ± 2.5 and 5.6 ± 2.8, respectively. The mean EQ-5D Weighted
Health Utility Index score [WHUI] (0–1 scale, 0 = worst health
imaginable, 1 = perfect health) and global health rating were 0.5
± 0.3 and 56.4 ± 23.7, respectively. Patients with “mild” average
pain (ratings of 0 to 3) had signiﬁcantly higher EQ-5D WHUI
(0.65 ± 0.19) and global health ratings (63.8 ± 19.5) compared
to patients with “moderate” (ratings of 4 to 6) 0.52 ± 0.28 and
55.5 ± 21.4, and “severe” (ratings of 7 to 10) average pain 0.21
± 0.33 and 49.3 ± 29.2, respectively; p < 0.05 for most com-
parisons. Increasing levels of worst pain severity from “mild” to
“moderate” to “severe” also resulted in a similar corresponding
decrease in EQ-5D WHUI scores as well as global health ratings,
p < 0.05 for most comparisons. CONCLUSIONS: Pain severity
in diabetic peripheral neuropathy has a signiﬁcant impact on
patients’ perceived health status.
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OBJECTIVE: InDuo is the ﬁrst device to combine an insulin
injector and BG meter. The goal of this study was to assess and
compare patient preference for the integrated system (InDuo®)
versus the standard treatment (syringe vial and separate meter;
SVM). METHODS: In a randomized, multicenter, two-period
crossover study, patients with type 1 diabetes (N = 125, mean
age 42.1 ± 14.3 years, mean A1C 7.9 ± 1.2% and frequency of
screening BG monitoring 3.9/day) were randomized to use of
either InDuo or a separate meter (Ultra One Touch) and syringe
for 6 weeks and then switched to the alternate treatment for 6
additional weeks. Preference and satisfaction questionnaires
were completed at the end of the study. The efﬁcacy, safety and
actual use of InDuo were compared to SVM. RESULTS: Patients
using InDuo reported signiﬁcantly higher overall satisfaction as
345Abstracts
assessed with WHO DTSQ. Use of InDuo also resulted in sig-
niﬁcantly higher rating of insulin therapy, lack of interference
with lifestyle and ease of injecting when away from home.
Seventy-nine percent patients preferred treatment with InDuo
rather than SVM, with convenience, ease of use, and accuracy
being major factors (p < 0.001). Other important features that
resulted in testing of BG more often with InDuo than with a
SVM included speciﬁc features like the 5-second BG analysis
(60%) and small blood sample requirement (55%). For InDuo
91% used BG memory several times a week (66% used doser
memory several times a week). Overall, the enrolled population
showed a signiﬁcant mean reduction of 0.54% in the A1C values
(p < 0.0001). Using combination device a large subset of patients
(32%) showed substantial increases in frequency of daily SMBG
monitoring (Mean 1 more reading/day). CONCLUSIONS: Use
of the InDuo was associated with improvements in patient treat-
ment satisfaction, which were reﬂected, in improved compliance
(more injections or blood tests per day) in a substantial portion
of the patients tested.
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OBJECTIVES: To examine admissions within the VA facility
among veterans with diabetes and the relationship between
number of admissions and type of antidiabetic therapy.
METHODS: Veterans with diabetes mellitus at a Texas Veterans
Health care System were selected by identifying those with an
ICD-9 code for diabetes from the outpatient ﬁle. Veterans who
received continuous care at the VA from FY 2000 to 2002 were
selected. Local Patient Treatment File and pharmacy ﬁle pro-
vided information on all VA admissions and prescription data.
A published method on attributing hospital utilization to dia-
betes based on ICD-9 codes and codes for diagnostic-related
groups from administrative databases were used. This method
classiﬁes admissions into 3 categories: clearly attributable to dia-
betes; probably attributable to diabetes; or not attributable to
diabetes. Type of medication therapy was deﬁned as the follow-
ing: oral therapy all 3 years; oral and insulin; insulin only; esca-
lating therapy; and other (i.e. insulin to oral or oral to no
medication). RESULTS: Of the 2285 veterans included in the
study, there were 1687 admissions at the VA facility over the 3-
year period. A total of 772 patients accounted for the admis-
sions. The mean length of stay per admission was 5.34 days (+/-
5.01). Of the admissions, 106 (6.4%) were clearly attributable
to diabetes; 578 (35.1%) were probably attributable to diabetes
and 964 (58.5%) were not attributable to diabetes. Comparisons
showed that mean rank for number of admissions for those on
oral therapy only was signiﬁcantly lower than the following:
both insulin and oral (Z = -5.43, p < 0.005); insulin only (Z =
-4.36, p < 0.005); escalating therapy (Z = -6.67, p < 0.005) and
other (Z = -7.01, p < 0.005). CONCLUSIONS: Approximately
40% of admissions among veterans with diabetes were either
clearly attributable or probably attributable to diabetes. Receiv-
ing oral therapy only was associated with fewer number of hos-
pital admissions than those on more intense therapy.
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OBJECTIVE: Glycemic control is a clinical outcome variable
often used in diabetes intervention research. Misconceptions
about A1C (glycosylated hemoglobin) and GHb (glycated hemo-
globin) measures can lead to the use of different glycemic control
measures within a study, threatening reliability and validity of
outcomes results. While A1C is the standard for long-term
glycemic control, the GHb measure may be more appropriate
among patients with hemoglobin variants like the sickle cell
factor and is sometimes used by clinicians who are aware that
their patient population has prevalence of these variants. GHb
measures are generally higher than A1Cs. The objective of this
study was to examine the impact on outcomes results of using
data from mixed (A1C or GHb) sites. METHODS: A conve-
nience sample of 183 patients from four patient care sites par-
ticipated in a cross-sectional survey measuring self-care
behaviors, diabetes history, and demographics. Glycemic control
data were gathered from patient charts and aggregated; one site
used GHb. Aggregated glycemic control data were analyzed with
other study variables. The GHb data were then converted to A1C
equivalents using a regression formula provided by the National
Glycohemoglobin Standardization Program (NGSP); analyses
were conducted again and compared. RESULTS: Mean glycemic
control for the sample with unconverted GHb readings was
8.40% (sd = 2.79); the mean for the A1C converted sample was
7.84% (sd = 1.89). Signiﬁcance of variable relationships varied
between the two, and the magnitude of relationship among 
correlated variables was greater among the unconverted GHb
sample. Mean glycemic control for both analyses revealed sta-
tistically signiﬁcant associations (p < 0.05) with readiness for all
diabetes self-care behaviors except vigorous exercise, but vari-
able associations among the group with unconverted GHbs were
stronger. CONCLUSIONS: If data within a study include dif-
ferent or non-standardized glycemic control measures, they
should be converted to be sure results reﬂect a standard variable.
PDB29
VALIDATION OF THE DIABETES RESOURCE CONSUMPTION
INDEX (DRCI): A RISK ADJUSTMENT TOOL FOR PREDICTING
HEALTH CARE RESOURCE USE AND COSTS
Joish VN1, Malone DC2,Wendel C3, Mohler MJ3
1University of Utah, Salt Lake City, UT, USA; 2University of Arizona,
Tucson, AZ, USA; 3Southern Arizona VA Health Care System,Tucson,
AZ, USA
OBJECTIVES: The purpose of this study was to validate a dia-
betes resource consumption index (DRCI). METHODS: The
data for this study was collected from the Southern Arizona Vet-
erans Affairs Health care System. A random split study sample
was created from the computerized medical record of veterans
with diabetes. Model estimation was done on the ﬁrst sample (n
= 367) and validation using the other 50% of the sample (n =
367). A Fisher’s z-statistic was used to assess the degree of 
correspondence between the predicted and actual values
